US20090305966A1 - Use of histones for therapeutic purposes - Google Patents

Use of histones for therapeutic purposes Download PDF

Info

Publication number
US20090305966A1
US20090305966A1 US11/920,050 US92005006A US2009305966A1 US 20090305966 A1 US20090305966 A1 US 20090305966A1 US 92005006 A US92005006 A US 92005006A US 2009305966 A1 US2009305966 A1 US 2009305966A1
Authority
US
United States
Prior art keywords
histone
thrombocytopenia
therapeutically effective
set forth
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/920,050
Other languages
English (en)
Inventor
Michael Zeppezauer
Reiner Class
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symbiotec GmbH Gesellschaft zur Forschung und Entwicklung der Biotechnologie
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to SYMBIOTEC GMBH GESELLSCHAFT FUR FORSCHUNG UND ENTWICKLUNG AUF DEM GEBIET DER BIOTECHNOLOGIE MBH reassignment SYMBIOTEC GMBH GESELLSCHAFT FUR FORSCHUNG UND ENTWICKLUNG AUF DEM GEBIET DER BIOTECHNOLOGIE MBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CLASS, REINER, ZEPPEZAUER, MICHAEL
Publication of US20090305966A1 publication Critical patent/US20090305966A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

  • the invention relates to the use of at least one human recombinant histone of H1 subtype and/or of its therapeutically effective segment, especially histone H1.3 for therapeutic purposes.
  • thrombocytopenia In complex pathological conditions such as acute myeloid leukemia, there is frequently observed to be a thrombocytopenia which may even be enhanced by a chemotherapeutic treatment of the leukemia. Thrombocytopenia is, however, also observed with other etiology. Since thrombocytopenia may lead to life-threatening internal hemorrhages, therapies for various pathological symptoms which may be the cause of the thrombocytopenia are frequently made particularly difficult.
  • the active substance of the invention shows on the one hand a positive result in the treatment of a hematological disorder such as leukemia, but on the other hand also a positive result in the treatment of the thrombocytopenia associated with the hematological disorders.
  • the active substance used in this case based on human recombinant H1.3 concentrations 37.5 mg/qm 2 of body surface area etc., having been administered in a 0.9% NaCl solution intravenously 3 times a week over a period of about 4 hours.
  • the platelets in peripheral blood are on the ordinate in a number of from 0 to 40 ⁇ 10 9 .
  • Treatment with active substance of the invention for three weeks is shown on the abscissa, the platelet count measured for the patient before the first treatment being greatly reduced at about 8 ⁇ 10 9 .
  • three drip infusions take place per week with in each case 4 hours per infusion, with the 1st to 3rd infusion on the 1st, 3rd and 5th day in the first week, with the 4th to 6th infusion on the 8th, 10th and 12th day in the second week and finally with the 7th to 9th infusion on the 15th, 17th and 19th day in the 3rd week.
  • the appended diagram shows at the start of the second week up to conclusion of the treatment in the third week a jump in the platelet count after the 5th day of treatment and then a continuous rise in the platelet count from the 8th to the subsequent 19th day of treatment and a further slower rise in the platelet count at the first control examination on the 29th day and at a later discharge day FU1 of the patient without further addition of the active substance of the invention, the finally measured platelet count being, as already stated, about 32.5 ⁇ 10 9 .
  • the invention is not restricted to the use of human recombinant H1.3. Because of the close relationship of the H1 subtypes, it is obvious to a skilled worker also to employ as active substance other human recombinant H1 subtypes as basis for the active substance of the invention.
  • the active substance of the invention preferably consists of the complete unshortened subtypes of histone proteins.
  • the therapeutically effective segment of which he is capable directly on the basis of his expert knowledge and experience without outstanding innovative contributions being necessary in this case.
  • Such therapeutically effective histone segments therefore lie within the range of equivalents of the teaching of the invention disclosed herein.
  • the invention further discloses the therapeutic teaching of employing, when there is a threatening or incipient primary disorder which, experience has shown, may result in thrombocytopenia, the active substance of the invention prophylactically against a threatening thrombocytopenia even if, unlike leukemia, the active substance of the invention is not effective against the primary disorder.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US11/920,050 2005-05-10 2006-05-04 Use of histones for therapeutic purposes Abandoned US20090305966A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005022319A DE102005022319A1 (de) 2005-05-10 2005-05-10 Verwendung von Histonen zu therapeutischen Zwecken
DE102005022319.2 2005-05-10
PCT/EP2006/004167 WO2006119912A2 (de) 2005-05-10 2006-05-04 Verwendung von histonen zu therapeutischen zwecken

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/004167 A-371-Of-International WO2006119912A2 (de) 2005-05-10 2006-05-04 Verwendung von histonen zu therapeutischen zwecken

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/758,950 Continuation US8962562B2 (en) 2005-05-10 2013-02-04 Use of histones for therapeutic purposes

Publications (1)

Publication Number Publication Date
US20090305966A1 true US20090305966A1 (en) 2009-12-10

Family

ID=37310925

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/920,050 Abandoned US20090305966A1 (en) 2005-05-10 2006-05-04 Use of histones for therapeutic purposes
US13/758,950 Expired - Fee Related US8962562B2 (en) 2005-05-10 2013-02-04 Use of histones for therapeutic purposes
US14/588,836 Abandoned US20150119331A1 (en) 2005-05-10 2015-01-02 Use of Histones for Therapeutic Purposes

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/758,950 Expired - Fee Related US8962562B2 (en) 2005-05-10 2013-02-04 Use of histones for therapeutic purposes
US14/588,836 Abandoned US20150119331A1 (en) 2005-05-10 2015-01-02 Use of Histones for Therapeutic Purposes

Country Status (12)

Country Link
US (3) US20090305966A1 (de)
EP (1) EP1879609B1 (de)
JP (2) JP2008540473A (de)
KR (3) KR20080007351A (de)
CN (1) CN101171027A (de)
CA (2) CA2811995A1 (de)
DE (1) DE102005022319A1 (de)
ES (1) ES2461564T3 (de)
HU (1) HUE027070T2 (de)
PL (1) PL1879609T3 (de)
PT (1) PT1879609E (de)
WO (1) WO2006119912A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005022319A1 (de) * 2005-05-10 2006-11-23 Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der Biotechnologie Mbh Verwendung von Histonen zu therapeutischen Zwecken

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818763A (en) * 1984-01-12 1989-04-04 Volker Rusch Biologically active substance with hormonal properties, production process thereof and utilization of histones for medical purposes
US5571686A (en) * 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
US5578571A (en) * 1990-01-04 1996-11-26 Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der Biotechnologie Mbh Cytostatic or cytotoxic combination of active substances for use in therapeutic procedures
US6468537B1 (en) * 1999-04-28 2002-10-22 The Board Of Trustees Of Northwestern University Localization of major peptide autoepitopes for nucleosome specific T cells of systemic lupus erythematosus
US20030017987A1 (en) * 1997-04-11 2003-01-23 Michael Zeppezauer Therapeutic, prophylactic, and diagnostic agent for cancer, useful for characterizing cancer cells with individual properties
US6884423B1 (en) * 1998-08-13 2005-04-26 Symbiotec Gmbh Antimicrobial histone H1 compositions, kits, and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3834589A (en) 1988-05-31 1990-01-05 Schering Biotech Corporation Method of treating myeloid leukemias
DE19715149A1 (de) * 1997-04-11 1998-10-15 Symbiotec Gmbh Krebstherapeutikum und Diagnose zur Charakterisierung von Krebszellen mit individueller Eigenschaft
DE10001113A1 (de) * 2000-01-13 2001-07-26 Strathmann Ag & Co Rekombinante Herstellung von humanen Histon 1-Subtypen sowie deren Verwendung für therapeutische Zwecke
US7931897B2 (en) 2001-02-07 2011-04-26 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hematopoietic tumors
JP2004519476A (ja) 2001-02-22 2004-07-02 シンビオテック・ゲゼルシャフト・ミット・ベシュレンクター・ハフツンク 血小板凝集防止用組成物及び方法
JP2002355048A (ja) * 2001-05-31 2002-12-10 Communication Research Laboratory リボヌクレオチド還元酵素ｒ１とその阻害ペプチド
DE10230223A1 (de) * 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
US20040146585A1 (en) * 2002-10-31 2004-07-29 Oregon Health & Science University Use of thiol-based compositions in treating chemotherapeutic agent-induced thrombocytopenia
DE102005022319A1 (de) * 2005-05-10 2006-11-23 Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der Biotechnologie Mbh Verwendung von Histonen zu therapeutischen Zwecken

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818763A (en) * 1984-01-12 1989-04-04 Volker Rusch Biologically active substance with hormonal properties, production process thereof and utilization of histones for medical purposes
US5182257A (en) * 1984-01-12 1993-01-26 Volker Rusch Use of pure histones h1 and h2a:h2b dimers in therapeutic methods
US5578571A (en) * 1990-01-04 1996-11-26 Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der Biotechnologie Mbh Cytostatic or cytotoxic combination of active substances for use in therapeutic procedures
US5571686A (en) * 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
US20030017987A1 (en) * 1997-04-11 2003-01-23 Michael Zeppezauer Therapeutic, prophylactic, and diagnostic agent for cancer, useful for characterizing cancer cells with individual properties
US6884423B1 (en) * 1998-08-13 2005-04-26 Symbiotec Gmbh Antimicrobial histone H1 compositions, kits, and methods of use thereof
US6468537B1 (en) * 1999-04-28 2002-10-22 The Board Of Trustees Of Northwestern University Localization of major peptide autoepitopes for nucleosome specific T cells of systemic lupus erythematosus

Also Published As

Publication number Publication date
ES2461564T3 (es) 2014-05-20
KR20140137462A (ko) 2014-12-02
JP2013151573A (ja) 2013-08-08
JP5667238B2 (ja) 2015-02-12
US20150119331A1 (en) 2015-04-30
JP2008540473A (ja) 2008-11-20
US8962562B2 (en) 2015-02-24
DE102005022319A1 (de) 2006-11-23
CA2608019A1 (en) 2006-11-16
CA2608019C (en) 2013-07-02
PT1879609E (pt) 2014-06-09
WO2006119912A2 (de) 2006-11-16
CA2811995A1 (en) 2006-11-16
HUE027070T2 (en) 2016-08-29
EP1879609A2 (de) 2008-01-23
KR20130099207A (ko) 2013-09-05
US20140148391A1 (en) 2014-05-29
KR20080007351A (ko) 2008-01-18
EP1879609B1 (de) 2014-03-12
PL1879609T3 (pl) 2014-08-29
WO2006119912A3 (de) 2007-04-12
CN101171027A (zh) 2008-04-30

Similar Documents

Publication Publication Date Title
Sarkar et al. Does nitric oxide regulate smooth muscle cell proliferation? A critical appraisal
US20020160008A1 (en) Treatment of diabetes
WO2009034134A3 (en) Use of natriuretic peptides for treating angioedema syndromes
EA201270292A1 (ru) Терапия глатирамером ацетатом с низкой кратностью
Huh et al. YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice
Deng et al. Effect of neuroinflammation on ABC transporters: possible contribution to refractory epilepsy
RU2009118962A (ru) Применение антагонистов il-1 для лечения подагры и псевдоподагры
Prajapati et al. Usefulness of exchanged protein directly activated by cAMP (Epac) 1-inhibiting therapy for prevention of atrial and ventricular arrhythmias in mice
Wiersma et al. Derailed proteostasis as a determinant of cardiac aging
Dimitrijević et al. Effect of neuropeptide Y on inflammatory paw edema in the rat: involvement of peripheral NPY Y1 and Y5 receptors and interaction with dipeptidyl-peptidase IV (CD26)
US8962562B2 (en) Use of histones for therapeutic purposes
JP2009524612A (ja) 多発性硬化症を治療及び／又は予防するための方法、ならびに多発性硬化症の間欠的治療用及び／又は間欠的予防用の薬剤を製造するためのエリスロポエチンの使用
CA2543507A1 (en) Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions
EP0942749A2 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin-antagonisten und inhibitoren der hautmastzell-degranulation
EP0669824B1 (de) Verwendung von kardiotonischen Mitteln und Inhibitoren der Stickstoffoxidsynthese zur Linderung von pathologisch verringertem Blutdruck
Lok et al. Neuronal low-density lipoprotein receptor-related protein 1 (LRP1) enhances the anti-apoptotic effect of intravenous immunoglobulin (IVIg) in ischemic stroke
Dembinski et al. The role of capsaicin-sensitive sensory neurons and nitric oxide in regulation of gastric mucosal growth
Moroji et al. A behavioral pharmacological study on CCK-8 related peptides in mice
US11351229B2 (en) Combination therapies for treating infantile spasms and other treatment resistant epilepsies
Shigyo et al. Pituitary adenylate cyclase activating peptide regulates neurally mediated airway responses
Liu et al. The role of HMGB1 in neuroinflammation and tissue repair: A potential therapeutic target for depression?
Kotwani et al. A prospective randomised study comparing intravenous magnesium sulphate and sublingual nitroglycerine spray in attenuating haemodynamic responses to laryngoscopy and intubation
Tsuchida et al. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses
WO2005058345A1 (en) A treatment for necrotizing enterocolitis
US20200121697A1 (en) Methods for diagnosing and treating cachexia

Legal Events

Date Code Title Description
AS Assignment

Owner name: SYMBIOTEC GMBH GESELLSCHAFT FUR FORSCHUNG UND ENTW

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZEPPEZAUER, MICHAEL;CLASS, REINER;REEL/FRAME:022036/0440;SIGNING DATES FROM 20071106 TO 20071107

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION